Nebivolol, an FDA-Approved Drug, Has General Antibacterial and Antibiofilm Effects and Increases Tolerance to Ciprofloxacin.

Pharmaceuticals (Basel)

Avram and Stella Goldstein-Goren Department of Biotechnology Engineering, Ben Gurion University of the Negev, Beer Sheva 84105, Israel.

Published: November 2024

Background: The repurposing of approved drugs for new activities is gaining widespread attention, including drugs that have antibacterial properties. Nevertheless, besides the benefits of repurposing drugs, the discovery of new antibiotic activity in commonly used medicines raises concerns about inducing antibiotic tolerance and resistance due to the stress produced by the drugs. We found that nebivolol, which is used to treat hypertension, also has antibacterial activity.

Methods: The antibacterial activity of nebivolol was tested by disc diffusion and kinetic O.D.

Measurements: Antibiofilm activity was determined by crystal violet staining.

Results: Nebivolol has antibiotic and antibiofilm activity against several bacteria. However, its effect on 's growth is limited, and it promotes biofilm formation. In addition, exposure to nebivolol induces resistance to ciprofloxacin but increases sensitivity to tobramycin.

Conclusions: Nebivolol has antibiotic activity against several bacteria tested but is less effective and possibly detrimental in infections. The use of nebivolol, together with other antibiotics, should be further tested and carefully considered.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11597176PMC
http://dx.doi.org/10.3390/ph17111472DOI Listing

Publication Analysis

Top Keywords

antibiotic activity
8
antibiofilm activity
8
nebivolol antibiotic
8
activity bacteria
8
nebivolol
7
activity
5
nebivolol fda-approved
4
fda-approved drug
4
drug general
4
antibacterial
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!